Company news: Shire, Sanofi

Shire announced Wednesday that it is looking to expand the indication for its ADHD medication Vyvanse. The company is seeking approval for use of the stimulant as a maintenance drug for children between the ages of 6 and 17. It is currently cleared for maintenance therapy among adults. Approval would make it the only stimulant approved for maintenance among this age group. FDA's action date is April 29, 2013.

Sanofi is expected to clarify layoff plans at meetings September 25 and October 3, reported Reuters, which attributed the information to union sources. Reuters' sources said they expect Sanofi to cut about 2,500 research and support jobs in France. Sanofi told Reuters meeting dates had not been set, but that it will present its employment plans to the works council this month.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.